نتایج جستجو برای: مدل tam

تعداد نتایج: 126565  

Journal: :Cancer research 2009
Andrea S Blevins-Primeau Dongxiao Sun Gang Chen Arun K Sharma Carla J Gallagher Shantu Amin Philip Lazarus

Tamoxifen (TAM) is a selective estrogen receptor modulator widely used in the prevention and treatment of breast cancer. A major mode of metabolism of the major active metabolites of TAM, 4-OH-TAM and endoxifen, is by glucuronidation via the UDP-glucuronosyltransferase (UGT) family of enzymes. To examine whether polymorphisms in the UGT enzymes responsible for the glucuronidation of active TAM ...

منعم, حسین, نعمت اللهی, محترم, گراوند, علی,

مقدمه: مدارک پزشکی الکترونیکی، یکی از فناوری­های نوین برای بهره­برداری از اطلاعات سلامت است که به عنوان سیستمی با ارزش جهت دسترسی به اطلاعات بیمار در بیمارستان­ها شناخته شده است و برای اجرای موفق آن مانند هر سیستم دیگری باید در ابتدا فاکتورهای مؤثر بر پذیرش و استفاده از آن را سنجید. هدف از این مطالعه بررسی نظام­ مند مقالات منتشر شده درباره عوامل مؤثر بر پذیرش مدارک پزشکی الکترونیکی براساس تئوری...

ژورنال: :مجله انفورماتیک سلامت و زیست پزشکی 0
محترم نعمت اللهی mohtaram nematollahi علی گراوند ali garavand m.sc. student in health information technology, health information management dept., school of medical information science & management, shiraz university of medical sciences, shiraz, iran.کارشناسی ارشد فناوری اطلاعات سلامت، گروه مدیریت اطلاعات سلامت، دانشکده مدیریت و اطلاع رسانی پزشکی، دانشگاه علوم پزشکی شیراز ، شیراز، ایران. حسین منعم hossein monem

مقدمه: مدارک پزشکی الکترونیکی، یکی از فناوری­های نوین برای بهره­برداری از اطلاعات سلامت است که به عنوان سیستمی با ارزش جهت دسترسی به اطلاعات بیمار در بیمارستان­ها شناخته شده است و برای اجرای موفق آن مانند هر سیستم دیگری باید در ابتدا فاکتورهای مؤثر بر پذیرش و استفاده از آن را سنجید. هدف از این مطالعه بررسی نظام­ مند مقالات منتشر شده درباره عوامل مؤثر بر پذیرش مدارک پزشکی الکترونیکی براساس تئوری...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2005
Priyanka Parte David Kupfer

Tamoxifen (TAM), used as the endocrine therapy of choice for breast cancer, undergoes metabolism primarily forming N-desmethyltamoxifen, 4-hydroxytamoxifen, alpha-hydroxytamoxifen, and tamoxifen-N-oxide (TNO). Our earlier studies demonstrated that flavin-containing monooxygenases (FMOs) catalyze the formation of TNO. The current study demonstrates that human FMO1 and FMO3 catalyze TAM N-oxidati...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2011
Jennifer Selever Guowei Gu Michael T Lewis Amanda Beyer Matthew H Herynk Kyle R Covington Anna Tsimelzon Gabriela Dontu Patrick Provost Attilio Di Pietro Ahcène Boumendjel Kathy Albain Lucio Miele Heidi Weiss Ines Barone Sebastiano Ando Suzanne A W Fuqua

PURPOSE Tamoxifen (Tam) is the most prescribed hormonal agent for treatment of estrogen receptor α (ERα)-positive breast cancer patients. Using microarray analysis, we observed that metastatic breast tumors resistant to Tam therapy had elevated levels of Dicer. EXPERIMENTAL DESIGN We overexpressed Dicer in ERα-positive MCF-7 human breast cancer cells and observed a concomitant increase in exp...

2003
Heshan Sun

Generally speaking, technology acceptance model (TAM, Davis, et al., 1989; Davis, 1989) is a successful model and prior studies have explored the TAM from different perspectives and many antecedents have been identified. However, the overview of TAM shows that the explanatory power of TAM is limited. Furthermore, more and more inconsistencies in results appeared along with the development of TA...

Journal: :Cancer research 1997
D Li Y Dragan V C Jordan M Wang H C Pitot

To assess the effects of chronic administration of tamoxifen (TAM) and toremifene (TOR) on genetic damage related to carcinogenesis, we measured DNA adduct formation by (32)P-postlabeling in liver, kidney, and uterus of Fischer rats given TAM or TOR in the diet for 18 months. TAM induced high levels of DNA adducts in the liver in a dose-dependent manner. The total adduct levels were 3000 +/- 87...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1999
J N Ingle V J Suman P A Johnson J E Krook J A Mailliard R H Wheeler C L Loprinzi E A Perez V C Jordan M Dowsett

The goals of this clinical trial involving postmenopausal women with metastatic breast cancer were to: (a) examine the effects of letrozole on tamoxifen (TAM) pharmacokinetics; (b) examine estrogen suppression in patients receiving TAM plus letrozole; and (c) evaluate tolerability, toxicity, objective response, and time to progression for the combination. Postmenopausal women with measurable or...

Journal: :Cancer 1999
J N Ingle V J Suman C G Kardinal J E Krook J A Mailliard M H Veeder C L Loprinzi R J Dalton L C Hartmann C A Conover M N Pollak

BACKGROUND Tamoxifen (TAM) is generally considered the hormonal agent of choice for postmenopausal women with hormone receptor positive breast carcinoma. The somatostatin analogues, including octreotide, have demonstrated inhibition of breast carcinoma cell lines and multiple endocrinologic actions, including reduction of insulin-like growth factor I (IGF-I), a potent mitogen for breast carcino...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2010
Charles E Wood Jay R Kaplan M Babette Fontenot J Koudy Williams J Mark Cline

PURPOSE Combination estrogen + progestin therapy has been associated with increased breast cancer risk in postmenopausal women. Selective estrogen receptor modulators (SERM) are potential alternatives to progestins, although the endometrial safety of estrogen + SERM co-therapies is not known. The goal of this study was to evaluate the endometrial profile of low-dose estradiol and the SERM tamox...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید